Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.
How this was made

The 30-second read
Why it matters
Near-term trading focus is likely on (1) durability of cash-flow positivity and operating profitability, (2) whether the Access First initiatives translate into sustained prescription growth, and (3) the credibility of the Q4 2026 Phase II EoE data timeline that could support pediatric exclusivity discussions. The VOQUEZNA exclusivity litigation is a key overhang for valuation and competitive dynamics.
Market read
Company-specific earnings and guidance details plus a defined clinical catalyst window can drive biotech positioning, while exclusivity litigation adds headline risk.
What to watch
The VOQUEZNA exclusivity litigation and the IQVIA methodology adjustment could complicate interpretation of prescription trends and future category share assumptions.
Background
Phathom’s call centers on a commercial pivot labeled “Access First,” aiming to improve adoption through prior authorization education and a $0 copay program via BlinkRx, alongside continued investment in late-stage trials and GI portfolio expansion.
Ticker impact
Phathom reported Q3 revenue growth to $84.7M, reiterated 2026 guidance of $310M-$325M, and discussed Q4 2026 Phase II EoE data timing.
Likely upward bias as investors price in improving cash generation and near-term clinical catalysts, with volatility around the exclusivity litigation.
The article contains multiple company-specific operating datapoints (revenue, cash flow, prescriptions) plus a concrete upcoming clinical milestone (Phase II EoE data in Q4 2026) and an ongoing legal overhang tied to VOQUEZNA exclusivity.
Market effects
Highlights continued commercialization focus in GI specialty pharma, including prior authorization workflow optimization and channel partnerships.
No clear regional market mechanism beyond US biotech sentiment.
Limited, as the catalysts described are company-specific and US regulatory/clinical-path related.
Counterpoint
The cash-flow and revenue momentum may still be fragile if gross-to-net discounts remain elevated and prior authorization success depends on execution that could vary by office and payer.
Key entities
- companyPhathom Pharmaceuticals, Inc.
Subject of the earnings call summary, providing Q3 operating metrics, 2026 revenue guidance, and upcoming Phase II EoE timing.
- productVOQUEZNA
Phathom’s GI therapy discussed in the context of exclusivity litigation and commercial adoption initiatives.
- companyBDR Pharmaceuticals
Litigant challenging the FDA’s 10-year NCE exclusivity grant for VOQUEZNA under the GAIN Act.
- partnerBlinkRx
Pharmacy partnership used to deliver a $0 copay offering and influence prior authorization and refill dynamics.
- regulatorFDA
Regulatory authority referenced for NCE exclusivity and for future Phase III design and pediatric exclusivity discussions.


